{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:03:59Z","timestamp":1784610239308,"version":"3.55.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Von Hippel-Lindau (VHL) disease is a rare familial autosomal dominant disorder with an incidence rate of approximately 1 in 36,000. It primarily results from mutations or inactivation of the VHL tumor suppressor gene located on chromosome 3p25-p26. The hallmark of this disease is hereditary hemangioblastoma, which can affect multiple organs and systems, including the brain (commonly infratentorial), spinal cord, retina, and internal organs such as the kidneys, adrenal glands, and pancreas. Less commonly, lesions may include papillary cystadenomas and endolymphatic sac tumors (ELST), which can form in the epididymis or broad ligament. The leading causes of death in these patients are hemangioblastomas and renal cell carcinoma of the central nervous system. Due to the multidisciplinary nature of the disease, diagnosis and management require a multidisciplinary team (MDT) consultation and collaboration among various specialties. Clinical diagnosis, genetic implications, and prognosis must be assessed comprehensively, with genetic testing confirming the diagnosis. Cases of VHL are exceptionally rare in clinical practice, and there remains a significant unmet need for effective treatments, particularly in rare tumors. Misdiagnosis and mistreatment are common, and repeated surgical interventions can exacerbate kidney damage. Early and accurate diagnosis, followed by proactive treatment, can significantly improve prognosis. Recently, our department admitted two patients with VHL-deficient renal cell carcinoma. Through surgery, radiofrequency ablation, and subsequent targeted therapy, the therapeutic outcomes were highly favorable. This report introduces the treatment of these two cases and provides a literature review on the current progress in the diagnosis, treatment, and prognosis of VHL-deficient renal cell carcinoma. Additionally, it discusses data on the screening of VHL patients and their close relatives, while emphasizing the optimization of individualized management for renal cell carcinoma to enhance the understanding, diagnosis, and treatment of the disease.<\/jats:p>","DOI":"10.3389\/fonc.2026.1645910","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T04:19:37Z","timestamp":1784607577000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Diagnosis and treatment report and literature review of 2 cases of VHL-deficient renal cell carcinoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Yanchen","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Urology, Weifang people\u2019s Hospital, Shandong Second Medical University","place":["Weifang, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongbin","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Urology, Weifang people\u2019s Hospital, Shandong Second Medical University","place":["Weifang, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Ren","sequence":"additional","affiliation":[{"name":"School of Nursing, Shandong Second Medical University","place":["Weifang, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine, Shandong Second Medical University","place":["Weifang, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingxuan","family":"Li","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine, Shandong Second Medical University","place":["Weifang, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Weifang people\u2019s Hospital, Shandong Second Medical University","place":["Weifang, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/cm9.0000000000002108","article-title":"Cancer statistics in China and United States, 2022: profiles, trends, and determinants","volume":"135","author":"Xia","year":"2022","journal-title":"Chin Med J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.eururo.2018.08.036","article-title":"Epidemiology of renal cell carcinoma","volume":"75","author":"Capitanio","year":"2019","journal-title":"Eur Urol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.humpath.2018.01.010","article-title":"Trends in reporting histological subtyping of renal cell carcinoma: association with cancer center type","volume":"74","author":"Gansler","year":"2018","journal-title":"Hum Pathol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-8-387","article-title":"Smoking, environmental tobacco smoke, and risk of renal cell cancer: a population-based case-control study","volume":"8","author":"Theis","year":"2008","journal-title":"BMC Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2018.79.1905","article-title":"Epidemiology and risk factors for kidney cancer","volume":"36","author":"Scelo","year":"2018","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1161\/hypertensionaha.120.14820","article-title":"Association of hypertension and blood pressure with kidney cancer risk: a nationwide population-based cohort study","volume":"75","author":"Kim","year":"2020","journal-title":"Hypertension"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002724","article-title":"The influence of obesity-related factors in the etiology of renal cell carcinoma\u2014A mendelian randomization study","volume":"16","author":"Johansson","year":"2019","journal-title":"PloS Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/ejhg.2010.175","article-title":"Von Hippel\u2013Lindau disease: a clinical and scientific review","volume":"19","author":"Maher","year":"2011","journal-title":"Eur J Hum Genet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0376-2491.2018.28.002","article-title":"Expert consensus on the diagnosis and treatment of von Hippel-Lindau disease in China","volume":"98","author":"Gong","year":"2018","journal-title":"Chin Med J"},{"key":"B10","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.eururo.2022.03.006","article-title":"European Association of Urology guidelines on renal cell carcinoma: the 2022 update","volume":"82","author":"Ljungberg","year":"2022","journal-title":"Eur Urol"},{"key":"B11","article-title":"Treatment strategies for hereditary kidney cancer: current recommendations and updates","volume":"34","author":"Singh","year":"2022","journal-title":"Discov Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/s1569-9056(18)31988-2","article-title":"Risk factors for survival in patients with von Hippel-Lindau disease","volume":"55","author":"Wang","year":"2018","journal-title":"J Med Genet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.102193","article-title":"Advancements in understanding the molecular mechanisms and clinical implications of Von Hippel-Lindau syndrome: a comprehensive review","volume":"51","author":"Wang","year":"2025","journal-title":"Transl Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1053\/j.ackd.2013.10.001","article-title":"Hereditary kidney cancer syndromes","volume":"21","author":"Haas","year":"2014","journal-title":"Adv Chronic Kidney Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-019-1206-2","article-title":"Growth characteristics and therapeutic decision markers in von Hippel-Lindau disease patients with renal cell carcinoma","volume":"14","author":"Schuhmacher","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.01.122","article-title":"Metachronous bilateral renal cell carcinoma: risk assessment, prognosis and relevance of the primary-free interval","volume":"177","author":"Klatte","year":"2007","journal-title":"J Urol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410x.2009.08844.x","article-title":"Developments in the surgical management of sporadic synchronous bilateral renal tumours","volume":"105","author":"Lowrance","year":"2010","journal-title":"BJU Int"},{"key":"B18","article-title":"Management of bilateral synchronous renal cell carcinoma in a single versus staged procedure","volume":"16","author":"Jacobs","year":"2009","journal-title":"Can J Urol"},{"key":"B19","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2011.06.029","article-title":"Metastatic potential in renal cell carcinomas\u2264 7 cm: Swedish Kidney Cancer Quality Register data","volume":"60","author":"Gu\u00f0mundsson","year":"2011","journal-title":"Eur Urol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410x.2012.11173.x","article-title":"The correlation between size of renal cell carcinoma and its histopathological characteristics: a single center study of 1867 renal cell carcinoma cases","volume":"110","author":"Zhang","year":"2012","journal-title":"BJU Int"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410x.2009.08745.x","article-title":"A comparative population-based analysis of the rate of partial vs radical nephrectomy for clinically localized renal cell carcinoma","volume":"105","author":"Baillargeon-Gagn\u00e9","year":"2010","journal-title":"BJU Int"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2015.02.010","article-title":"Percutaneous cryoablation of stage T1b renal cell carcinoma: technique considerations, safety, and local tumor control","volume":"26","author":"Atwell","year":"2015","journal-title":"J Vasc Interventional Radiol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.08.039","article-title":"Cryoablation versus partial nephrectomy for clinical T1b renal tumors: a matched group comparative analysis","volume":"71","author":"Caputo","year":"2017","journal-title":"Eur Urol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.13130221","article-title":"Radiofrequency ablation versus radical nephrectomy: clinical outcomes for stage T1b renal cell carcinoma","volume":"270","author":"Takaki","year":"2014","journal-title":"Radiology"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2014.07.112","article-title":"Radio frequency ablation versus partial nephrectomy for clinical T1b renal cell carcinoma: long-term clinical and oncologic outcomes","volume":"193","author":"Chang","year":"2015","journal-title":"J Urol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/978-88-470-5693-0_25","article-title":"Update on ablative therapies of renal tumors","volume":"26","author":"D\u2019Andrea","year":"2016","journal-title":"Curr Opin Urol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-023-09779-7","article-title":"Percutaneous radiofrequency ablation is an effective treatment option for small renal masses, comparable to partial nephrectomy","volume":"33","author":"Pedraza-S\u00e1nchez","year":"2023","journal-title":"Eur Radio"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-22-1054","article-title":"FDA approval summary: belzutifan for von Hippel-Lindau disease\u2013associated tumors","volume":"28","author":"Fallah","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac234","article-title":"Neurological applications of belzutifan in von Hippel-Lindau disease","volume":"25","author":"Zhang","year":"2023","journal-title":"Neuro-Oncology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0679","article-title":"Belzutifan: a novel therapeutic for the management of von hippel\u2013lindau disease and beyond","volume":"20","author":"Curry","year":"2024","journal-title":"Future Oncol"},{"key":"B31","first-page":"25","article-title":"A new era of management of von Hippel\u2013Lindau disease\u2013associated tumors with belzutifan","volume":"29","author":"Haag","year":"2025","journal-title":"Clin J Oncol Nurs"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105109","article-title":"Fatal intracranial haemorrhage shortly after belzutifan initiation in von Hippel\u2013Lindau (VHL) disease-associated haemangioblastoma","volume":"10","author":"Shepherd","year":"2025","journal-title":"ESMO Open"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41431-022-01172-0","article-title":"Commentary: von Hippel\u2013Lindau disease: a clinical and scientific review","volume":"30","author":"Abedalthagafi","year":"2022","journal-title":"Eur J Hum Genet"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14215352","article-title":"The clinical and molecular features in the VHL renal cancers; close or distant relatives with sporadic clear cell renal cell carcinoma","volume":"14","author":"Cinque","year":"2022","journal-title":"Cancers"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(94)00391-h","article-title":"Von hippel-lindau disease","volume":"4","author":"Maher","year":"2004","journal-title":"Curr Mol Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1645910\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T04:19:42Z","timestamp":1784607582000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1645910\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":35,"alternative-id":["10.3389\/fonc.2026.1645910"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1645910","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"article-number":"1645910"}}